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Reactive oxygen species (ROS) caused oxidative stress plays a key role in carcinogenesis. The POU
domain transcription factor Oct-1 and catalase is closely associated with ROS. However, a correla-
tion between these two key proteins has not been demonstrated before. In this report, we show that
Oct-1 acts as an activator of catalase, by binding to the catalase promoter in hepatocellular carci-
noma (HCC) cell lines. In addition, we suggest that Oct-1 is downregulated by ROS via CpG island
methylation in its promoter. These ﬁndings contribute to a better understanding of the epigenetic
changes induced by ROS in the process of carcinogenesis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Reactive oxygen species (ROS) are involved in the multistage
process of carcinogenesis and induce both genetic and epigenetic
alterations [1,2]. ROS-induced DNA methylation is the most fre-
quent mechanism in the epigenetic regulation of gene expression
by ROS and plays a crucial role in the development of cancer [3].
In particular, hypermethylation of CpG islands in promoter regions
of tumor suppressor genes is frequently seen in tumor cells [4,5].
However, this change is reversible [6].
Catalase is an antioxidant that catalyzes degradation of H2O2
and plays a crucial role in protecting cells against ROS [7]. How-
ever, prolonged exposure to ROS downregulates catalase expres-
sion, via hypermethylation of a CpG island in the catalase
promoter [8]. Decreased expression of catalase in cancers [9,10]
is associated with tumor formation and metastasis [11–13].
Oct-1 is a member of the POU-domain transcription factor fam-
ily, which is ubiquitously expressed [14]. Oct-1, known to function
as both an activator [15] and a suppressor [16] of gene transcrip-chemical Societies. Published by E
S, bisulﬁte sequencing; ChIP,
ltransferase; EMSA, electro-
rcinoma; MSP, methylation-
methosulfate; ROS, reactive
iological Sciences and Seoul
k-gu, Seoul 151-742, Southtion, controls gene expression by interacting with an 8-bp octamer
motif (50-ATGCAAAT-30) and related sequences [17]. Many studies
have elucidated the role of Oct-1 in cell cycle regulation [18,19].
Recently, it has also been reported that Oct-1 acts as a sensor for
cellular stress [20].
Approximately 85–95% of liver cancer is hepatocellular carci-
noma (HCC), and annually this causes approximately half a million
deaths worldwide [21] also. Oxidative stress plays a key role in the
pathogenesis and progression of liver cancer [22]. A correlation be-
tween ROS and HCC has been demonstrated and, moreover, certain
genes, including E-cadherin and catalase, have been reported to be
methylated by ROS in HCC [8,23].
In this study, we analyzed Oct-1 promoter regulation via meth-
ylation and identiﬁed a link between the Oct-1 transcription factor
and catalase expression. In HCC cells, Oct-1 binds to the catalase
promoter and acts as an activator. We also found that ROS induce
methylation of CpG sites in the Oct-1 promoter. Overall, we
showed that ROS-induced methylation of the Oct-1 promoter can
be another mechanism by which catalase is downregulated by
ROS in HCC.
2. Materials and methods (see also Supplementary data)
2.1. Cell culture and treatments
Human hepatoma cells, Huh7 and Hep3B, were cultured
and treated with H2O2, menadione, PMS as previously described
[23]. For some experiments, the cells were pretreated withlsevier B.V. All rights reserved.
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(5-aza-dC) (Sigma–Aldrich) as previously described [8]. Cell trans-
fections were carried out using Fugene 6 reagent (Roche) accord-
ing to the manufacturer’s instructions. For shRNA experiments,
cells were transfected with shRNA-Oct-1 (NM_002697) and con-
trol shRNA (pLKO.1) (Sigma–Aldrich) using Fugene 6 (Roche).
72 h after transfection, Oct-1 protein expression was analyzedFig. 1. Oct-1 acts as a transcriptional activator of catalase (A) Huh7 and Hep3B cells w
luciferase expression vector (pRL-SV40), as a control for transfection efﬁciency and anal
expression was assessed by real-time RT-PCR. (C) Expression of Oct-1 was assessed by imm
were transfected with shRNA-Oct-1 and assessed by immunoblot. b-Actin served as an
Fig. 2. Oct-1 binds to the catalase promoter (A) ChIP analysis of Oct-1 on the catalase pr
was performed using nuclear protein extract prepared from Huh7 cells. Normal mouse Ig
or without mutation in the Oct-1 binding site. Huh7 cells were transfected with wild-type
site (Mut). The cells were cotransfected with pCMV/HA-Oct-1 or pCMV/HA control vectby immunoblotting. All other reagents were purchased from
Sigma.
2.2. Oligonucleotides
All the oligonucleotides used in this study are listed in
Supplementary Tables 1–4.ere co-transfected with pGL3-CAT and pCMV/HA-Oct-1, or pCMV/HA and a Renilla
yzed for luciferase activity. HA, pCMV/HA; Oct-1, pCMV/HA-Oct-1. (B) Oct-1 mRNA
unoblot analysis of cell lysates. b-Actin served as an internal control. (D) Huh7 cells
internal control. Catalase activity was measured using the cell lysate. C, control.
omoter was performed using an antibody to Oct-1. SM, DNA size marker. (B) EMSA
G was used as a positive control. (C) Oct-1-induced catalase promoter activities with
catalase promoter (CAT) or its derivative containing a mutation in the Oct-1 binding
or, as indicated.
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Methylation-speciﬁc polymerase chain reaction (MSP) was
performed as previously described [8]. Oct-1 primers were de-
signed usingMethyl Primer Express software (Applied Biosystems).
2.4. Statistical analysis
Data, represented as bar graphs, are expressed as the mean and
standard deviation of 3 independent experiments. All results in the
bar graphs are expressed as the fold change relative to untreated or
control cells.3. Results
3.1. Transcription factor Oct-1 acts as an activator of catalase
To analyze the effect of transcription factor Oct-1 on catalase
expression, Hep3B and Huh7 cells were transfected with HA-Oct-
1 and a dual luciferase assay was carried out. In both Hep3B andFig. 3. Reactive oxygen species downregulate Oct-1 expression in hepatocellular carcinom
menadione and 2 lM PMS (phenazine methosulfate) for 2 and 4 days, after which Oct-1
controls. SM, DNA size marker; Mena, menadione. (B) Huh7 and Hep3B cells were tre
Bisulﬁte-modiﬁed DNA was ampliﬁed with sodium bisulﬁte genomic sequencing (BS) pri
were treated as described in (A) and methylation-speciﬁc PCR (MSP) was performed. SM
treated with 300 lM H2O2 for 4 days and then incubated for a further 4 days following w
And Oct-1 expression was assessed by real-time RT-PCR and immunoblotting.Huh7 cells, catalase promoter activity in cells overexpressing
Oct-1 protein was approximately 2.5-fold greater than that in the
control cells (Fig. 1A). The patterns of change in Oct-1 mRNA and
protein levels, analyzed by real-time PCR and immunoblotting,
respectively, were similar to the pattern as promoter activity in
Oct-1-overexpressing cells (Fig. 1B and C). We performed addi-
tional immunoblot analyses and assay for catalase activity in
shRNA-Oct-1-transfected cells to conﬁrm the activator effect of
Oct-1 and found that both catalase protein levels and catalase
activity were decreased in Huh7 cells treated with Oct-1 shRNA
(Fig. 1D).
3.2. Oct-1 binds to the catalase promoter
Previous studies have shown that Oct-1 binds to octamer motif-
related sequences [17]. We used a ChIP assay to determine
whether Oct-1 protein binds to the catalase promoter. The data re-
vealed that Oct-1 binds to the catalase promoter (Fig. 2A). To fur-
ther clarify the binding of Oct-1 to the sequences (50-ATTAAATA-
30) located at -583 -576 within the catalase promoter, we also
performed EMSA (Fig. 2B). Oct-1 protein shifted the biotin-labeleda (HCC) cell lines. (A) Huh7 and Hep3B cells were treated with 300 lMH2O2, 20 lM
expression was assessed by immunoblot analysis. Catalase and b-actin were used as
ated as described in (A). Oct-1 expression was assessed by real-time RT-PCR. (C)
mers. h, unmethylated CpG site; j, methylated CpG site. (D) Huh7 and Hep3B cells
, DNA size marker; U, unmethylated DNA; M, methylated DNA. (E) Huh7 cells were
ithdrawal of H2O2. MSP was performed on genomic DNA isolated from these cells.
Fig. 4. N-Acetylcysteine and 5-aza-20-deoxycytidine restore Oct-1 expression in ROS-treated HCC cell lines. (A) Huh7 and Hep3B cells were treated with 300 lMH2O2, 20 lM
menadione and 2 lM PMS and/or 5 mM N-acetylcysteine and 2 lM 5-aza-dC for 4 days, after which MSP was performed on genomic DNA isolated from these cells. SM, DNA
size marker; U, unmethylated DNA; M, methylated DNA; Mena, menadione. (B) Oct-1 expression was assessed by real-time RT-PCR. (C) Oct-1 expression was assessed by
immunoblotting.
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(Fig. 2B, Lane 1) compared to the control (Fig. 2B, Lane 5) and the
speciﬁcity of Oct-1 binding was conﬁrmed by competitive inhibi-
tion with a 200-fold excess of unlabeled oligonucleotides (Fig. 2B,
Lane 4). We further conﬁrmed that it was the Oct-1 protein in the
shifted complex by performing a supershift with an antibody spe-
ciﬁc to Oct-1 using the nuclear extracts (Fig. 2B, Lane 2), or mouse
normal IgG, as a control (Fig. 2B, Lane 3). In addition, we performed
a dual luciferase assay using a catalase promoter with a point
mutation (50-ATTAAATA-30 ? 50-ATTACATA-30) within the Oct-1
binding site. Compared to the control, decreased promoter activity
was observed with this mutated promoter, even in Oct-1-over-
expressing cells (Fig. 2C).
3.3. ROS downregulate Oct-1 expression and this downregulation is
reversible in HCC cells
ROS downregulate catalase expression via hypermethylation of
a CpG island in its promoter [8] and Oct-1-deﬁcient cells are hyper-
sensitive to hydrogen peroxide [20]. To determine the effects of
prolonged exposure to ROS on Oct-1, we treated HCC cell lines with
ROS sources (H2O2 and menadione) for 4 days. In H2O2 treated
cells, cell proliferation decreased, while the number of apoptotic
cells slightly increased (Supplementary Fig. S1). Treatment of
Hep3B and Huh7 cells with ROS sources resulted in reduction of
Oct-1 protein (Fig. 3A) and messenger RNA (mRNA) (Fig. 3B), and
so did in Hela (Human epithelial carcinoma cell line) andHCT116 (Colorectal carcinoma cell line) cells (Supplementary
Fig. S2), as analyzed by immunoblotting and real-time RT-PCR,
respectively. To address the possibility of methylation of Oct-1
promoter, we treated the cells with ROS sources and analyzed
the Oct-1 promoter using BS (bisulﬁte sequencing) and MSP
(methylation speciﬁc PCR) (Fig. 3C and D). Methylation of the
Oct-1 CpG island was observed 4 days after treatment with ROS,
as determined by BS and MSP. These data showed that prolonged
ROS exposure results in the methylation of the CpG island in the
Oct-1 promoter and simultaneously downregulates Oct-1 expres-
sion in HCC cell lines.
To determine whether Oct-1 downregulation by ROS was
reversible, we treated Huh7 cells with H2O2 for 4 days, then re-
placed the media with fresh media lacking H2O2, and thereafter
incubated the cells for an additional 4 days. MSP analysis was per-
formed to determine the methylation status of the CpG island in
the Oct-1 promoter. The results showed that the CpG island was
demethylated and that Oct-1 mRNA levels and protein expression
recovered after the removal of ROS (Fig. 3E). These data indicate
that ROS-induced methylation of the Oct-1 promoter and that
downregulation of Oct-1 expression is reversible in HCC cell lines.
3.4. N-Acetylcysteine and 5-aza-dC restore Oct-1 expression
ROS-induced methylation of the Oct-1 promoter was inhibited
following the treatment with N-acetylcysteine, an antioxidant, or
with 5-aza-dC, a DNA methyltransferase 1 (DNMT1) inhibitor
Fig. 5. Expression of Oct-1 can inhibit invasiveness induced by ROS. (A) Oct-1 overexpressing and control Huh7 and Hep3B cells were tretaed with 300 lM H2O2 for 4 days.
Oct-1 and catalase expression were assessed by immunoblotting. b-Actin served as an internal control. C, non-treated control cells; H2O2, H2O2 treated control cells; Oct-1,
Oct-1 overexpressing cells treated with H2O2. (B) Oct-1 overexpressing and control Huh7 and Hep3B cells were treated with 300 lM H2O2 for 4 days. A matrigel invasion
assay was performed as described in the Materials and Methods. C, non-treated control cells; H2O2, H2O2 treated control cells; Oct-1, Oct-1 overexpressing cells treated with
H2O2.
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were restored in these cells. And the results showed that Oct-1
expression in the 5-aza-dC and ROS treated cells showed approxi-
mately 75% recovery of 5-aza-dC treated cells compared to the
control and ROS treated cells, which means approximately 75% of
Oct-1 reduction is caused by ROS-induced promoter methylation.
These results indicate a correlation between ROS and downregula-
tion of Oct-1 and methylation of the Oct-1 promoter.
3.5. Expression of Oct-1 can inhibit invasiveness induced by ROS
Although ROS increase invasiveness of the cancer cells, this pro-
cess can be inhibited by the expression of catalase [23]. In order to
study the effect of Oct-1 on cell invasiveness as Oct-1 activates cat-
alase expression, we performed the invasion assay using Oct-1
overexpressing Huh7 and Hep3B, which were transfected with
pRC/CMV-HA-Oct-1 and selected by G418. First, we conﬁrmed that
Oct-1 overexpressing cells showed increase in both Oct-1 and cat-
alase expression compared to the controls (Fig. 5A). Despite the re-
sults of invasion assay demonstrated the increase in cell invasion
by H2O2, Oct-1 expression inhibited the invasiveness (Fig. 5B).
These data indicate that the inhibition of invasiveness of the cancer
cells induced by ROS might be resulted from catalase upregulation
caused by Oct-1 expression.
4. Discussion
The studies we have described here provide novel insights into
the role of ROS and Oct-1 in HCC cell lines. First, Oct-1 binds to the
catalase promoter and acts as a transcriptional activator of the cat-
alase gene. Second, ROS downregulate Oct-1 expression via meth-
ylation of a CpG island in the Oct-1 promoter. These results suggest
that prolonged ROS exposure induces methylation of the Oct-1
promoter to downregulate Oct-1, which contributes to the down-
regulation of catalase expression.
Transcription factor Oct-1 is a stress sensor [20], and DNA dam-
age induces Oct-1 through a posttranscriptional mechanism and
increases Oct-1 DNA binding afﬁnity [24]. Under short-term expo-sure to ROS, the expression of catalase shows the same pattern of
change as Oct-1 expression (Supplementary Fig. S3). Our data, Oct-
1 binds to the catalase promoter to activate the expression of cat-
alase, and data from other studies, suggest another mechanism for
the regulation of catalase expression in HCC.
Oct-1 decreased after exposure to ROS for 24 h, which is consis-
tent with the change in mRNA [24]. However, to our knowledge,
thus far, no study has addressed the epigenetic regulation of the
Oct-1 promoter by ROS. In this study, we show that prolonged
exposure to ROS decreases Oct-1 expression, due to methylation
of the Oct-1 promoter. On the basis of the correlation between
the expression of Oct-1 and catalase, our ﬁndings imply that ROS
regulates catalase not only through a direct mechanism, but also
through an indirect one—downregulation of the transcriptional
activator Oct-1. This would further weaken the ability of the cells
to defend against ROS and increases their sensitivity to ROS. Mean-
while, Oct-1 expression inhibits invasiveness induced by ROS, thus,
Oct-1 dowenregulation by ROS can increase the cancer cells
invasion.
In this study, we identiﬁed a new role of ROS: triggering DNA
methylation of transcription factor Oct-1. Although our investiga-
tion did not uncover a speciﬁc functional pathway by which ROS
induce CpG island methylation in the Oct-1 promoter, our results
strongly suggest that ROS regulate the methylation status of the
Oct-1 promoter in HCC cells. Understanding the roles of ROS,
Oct-1, and catalase could lead to new therapeutic approaches for
targeting HCC.
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